Literature DB >> 7586397

Long-term outcome of cardiac surgery in patients with mitral stenosis and severe pulmonary hypertension.

J J Vincens1, D Temizer, J R Post, L H Edmunds, H C Herrmann.   

Abstract

BACKGROUND: Pulmonary hypertension increases perioperative risk in patients having mitral valve replacement, but most studies have included patients with mixed mitral valve disease and have not examined long-term outcome. METHODS AND
RESULTS: We retrospectively examined the results and predictors of outcome of cardiac surgery in 43 patients (age, 62 +/- 13 years [mean +/- SD]; 81% women) with a primary diagnosis of mitral stenosis and severe pulmonary hypertension (pulmonary artery systolic pressure > or = 60 mm Hg or mean pressure > or = 50 mm Hg). Patients with more than mild mitral regurgitation were excluded. Thirty-eight patients (88%) were in NYHA functional class III or IV, and 11 patients (26%) had an acute presentation requiring urgent surgery. Preoperative hemodynamics demonstrated a mean mitral valve area of 0.7 +/- 0.3 cm2, mean pulmonary artery pressure of 50 +/- 9 mm Hg, and pulmonary artery systolic pressure of 81 +/- 18 mm Hg. Other characteristics included right ventricular failure (18 patients), coronary artery disease (16 patients), and critical aortic stenosis (11 patients). Forty patients underwent mitral valve replacement with St Jude prostheses; 3 had open commissurotomy. Additional surgical procedures included aortic valve replacement (42%), coronary artery bypass graft surgery (26%), and tricuspid valvuloplasty (16%). There were 5 perioperative deaths (11.6%), and 7 other patients (16%) had major complications, including reoperation for hemorrhage, stroke, respiratory failure, myocardial infarction, or a > 30-day hospitalization. Univariate analysis of demographic, hemodynamic, and operative characteristics identified the following predictors of perioperative death (P < .05): acute presentation, clinical evidence of right ventricular failure, impaired left ventricular ejection fraction, and increased left ventricular diastolic pressure. Predictors of complications (P < .05) were acute presentation, ECG evidence of right ventricular hypertrophy, and elevated right ventricular systolic pressure. Multivariate analysis showed only acute presentation and right ventricular hypertrophy as predictors of perioperative death or major complications, respectively. Five- and 10-year actuarial survivals were 80% and 64%, respectively. The only predictor of long-term mortality was advanced age. Functional NYHA status was improved by one grade or more in 76% of survivors.
CONCLUSIONS: Patients referred to a tertiary care hospital in the United States with mitral stenosis and severe pulmonary hypertension often have other associated cardiac diseases and comorbid conditions. Cardiac surgery can be successfully performed with an acceptable mortality, and risk factors for poor perioperative outcome can be identified by preoperative clinical characteristics. Younger patients have the best long-term survival, and most survivors experienced long-term improvement in functional status.

Entities:  

Mesh:

Year:  1995        PMID: 7586397     DOI: 10.1161/01.cir.92.9.137

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  17 in total

Review 1.  Pathophysiology of valvular heart disease: implications for nuclear imaging.

Authors:  Blasé Carabello
Journal:  J Nucl Cardiol       Date:  2002 Jan-Feb       Impact factor: 5.952

2.  The short- and medium-term results of transcatheter closure of atrial septal defect with severe pulmonary arterial hypertension.

Authors:  Zhi-wei Huang; Zhi-xin Fan; Jian-tao Sun; Wei-min Li; Yan-qing Gao; Yi-hua Quan; Ya-ming Geng; Yan-yan Niu; Bing-xiang Wu
Journal:  Heart Vessels       Date:  2011-09-17       Impact factor: 2.037

3.  A retrospective comparison of inhaled milrinone and iloprost in post-bypass pulmonary hypertension.

Authors:  Kassiani Theodoraki; Apostolos Thanopoulos; Panagiota Rellia; Evangelos Leontiadis; Dimitrios Zarkalis; Konstantinos Perreas; Theophani Antoniou
Journal:  Heart Vessels       Date:  2017-07-17       Impact factor: 2.037

4.  Patient-prosthesis mismatch in the mitral position affects midterm survival and functional status.

Authors:  Denis Bouchard; Frédéric Vanden Eynden; Philippe Demers; Louis P Perrault; Michel Carrier; Raymond Cartier; Arsène J Basmadjian; Michel Pellerin
Journal:  Can J Cardiol       Date:  2010-12       Impact factor: 5.223

5.  Predictors of persistent pulmonary hypertension after mitral valve replacement.

Authors:  Sem Briongos Figuero; José Luis Moya Mur; Alberto García-Lledó; Tomasa Centella; Luisa Salido; Álvaro Aceña Navarro; Ana García Martín; Ignacio García-Andrade; Enrique Oliva; José Luis Zamorano
Journal:  Heart Vessels       Date:  2015-06-09       Impact factor: 2.037

6.  The impact of preoperative and postoperative pulmonary hypertension on long-term surgical outcome after mitral valve repair for degenerative mitral regurgitation.

Authors:  Takashi Murashita; Yukikatsu Okada; Hideo Kanemitsu; Naoto Fukunaga; Yasunobu Konishi; Ken Nakamura; Tadaaki Koyama
Journal:  Ann Thorac Cardiovasc Surg       Date:  2014-04-18       Impact factor: 1.520

Review 7.  WHO's in second?: A practical review of World Health Organization group 2 pulmonary hypertension.

Authors:  Sif Hansdottir; Dayna J Groskreutz; Brian K Gehlbach
Journal:  Chest       Date:  2013-08       Impact factor: 9.410

8.  Levosimendan and severe pulmonary hypertension during open heart surgery.

Authors:  Ferit Cicekcioglu; Ali Ihsan Parlar; Ozgur Ersoy; Kerem Yay; Alaa Hijazi; S Fehmi Katircioglu
Journal:  Gen Thorac Cardiovasc Surg       Date:  2008-11-12

9.  An excellent result of surgical treatment in patients with severe pulmonary arterial hypertension following mitral valve disease.

Authors:  Xiaochun Song; Cui Zhang; Xin Chen; Yongming Chen; Qiankun Shi; Yongsheng Niu; Jilai Xiao; Xinwei Mu
Journal:  J Cardiothorac Surg       Date:  2015-05-13       Impact factor: 1.637

10.  Effectiveness of prophylactic levosimendan in high-risk valve surgery patients.

Authors:  Ozgur Ersoy; Emre Boysan; Ertekin Utku Unal; Kerem Yay; Umit Yener; Ferit Cicekcioglu; Fehmi Katircioglu
Journal:  Cardiovasc J Afr       Date:  2013-08       Impact factor: 1.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.